Indeed, in lung, ovarian, prostate, and pancreatic cancers, FAK inhibitors combined with other anti-cancer drugs significantly reduced tumour growth, tumour volume, and tumour load; increased apoptosis; and improved survival in in vitro and in vivo studies [23,29,30,31]. Here, PTK2 is linked to familial pancreatic carcinoma.